



Contents lists available at ScienceDirect

International Journal of the Cardiovascular Academy

journal homepage: www.elsevier.com/locate/ijcac

Short communication

Physician preferences for management of patients with heart failure and arrhythmia

Ümit Yaşar Sinan^{a,*}, Mehdi Zoghi^b, on behalf of CAS-TR Group¹^a Istanbul University Institute of Cardiology, Department of Cardiology, Turkey^b Ege University School of Medicine, Department of Cardiology, Turkey

ARTICLE INFO

Article history:

Received 14 May 2017

Received in revised form 7 June 2017

Accepted 8 June 2017

Available online 8 June 2017

ABSTRACT

Heart failure (HF) is one of the most important causes of morbidity and mortality in the world. It is a progressive and irreversible disorder. Survey and questionnaires are helpful verify that real-life daily practice is keeping with what is recommended in the guidelines. In this questionnaire which is consisted of 32 questions about current diagnostic and therapeutic strategies of HF and arrhythmias, we aimed to evaluate awareness of physicians who are interested in HF and arrhythmias about current diagnostic and therapeutic strategies of HF.

This survey was conducted in university hospitals, state hospitals, training and research hospitals, private hospitals and medical centers in seven geographical region of Turkey between January and February 2017. The study groups were consisted of 177 physicians (163 cardiologists, 7 cardiovascular surgeons, 6 internal medicine physicians and 1 primary care physician). Less than half of the physicians (N:71, 40.1%) have used natriuretic peptides in the diagnosis of HF and 76.3% of physicians were aware of HF with mid-range EF (HFmrEF)—patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49%. Despite optimal medical therapy with diuretic, ACEIs, ARBs, BB and mineralocorticoid receptor antagonists (MRAs), the ratio of physicians who have >50% symptomatic patient population were 6.8%. In this patient, angiotensin receptor neprilysin inhibitor (ARNI) was the treatment choice among 62.7% of physicians. Interestingly, 10.2% of physicians have never heard before ARNI. While only 13.6% physicians had >30% patients with HFpEF, most of the physicians (30.5%) had between 21% and 30% patients with HFpEF.

In this questionnaire we want to see a picture from daily practice of physicians who are interested in heart failure. We aimed to measure awareness about current European Society of Cardiology (ESC) heart failure guideline recommendations, new classification of HF according to LVEF and new diagnostic and therapeutic improvements.

© 2017 The Society of Cardiovascular Academy. Production and hosting by This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Istanbul University Institute of Cardiology, Cardiology Department, Istanbul University Institute of Cardiology, Keycihatun District, Haseki Adivar Street, Fatih, Istanbul, Turkey.

E-mail address: umit.sinan@istanbul.edu.tr (Ü.Y. Sinan).

¹ Gülay Gök, MD, Haşim Mutlu, MD, Arzu Neslihan Akgün, MD, Özlem Yıldırım Türk, MD, Veli Polat, MD, Şerife Aysen Helvacı, MD, Mevlüt Demir, MD, Emine Gazi, MD, Gönül Açıksarı, MD, Perihan Varım, MD, Hasan Kaya, MD, Suat Demirkıran, MD, Serkan Kahraman, MD, Gülsüm Meral Yılmaz, MD, Onur Dalgıç, MD, Ramazan Düz, MD, Hülya Odaş Bükün, MD, Fatih Kahraman, MD, Macit Kalçık, MD, Ersel Onrat, MD, Sahin Bozok, MD, Selami Söylemez, MD, Emre Demir, MD, Bülent Özlek, MD, Ahmet Akyol, MD, Derya Baykız, MD, İsa Öner Yüksel, MD, Murat Esin, MD, Tarık Kıvrak, MD, Turhan Turhan, MD, Servet Altay, MD, Rojhat Altındağ, MD, Mehmet Kadri Akboğa, MD, Çiğdem Koca Tanı, MD, Uğur Kocabaş, MD, Mehmet Kalender, MD, Mustafa Beyazıt Alkan, MD, Reşit Coşkun, MD, Hakan Özkan, MD, Esra Erdem Palaz, MD, Yeliz Sökmen, MD, Abdullah Sökmen, MD, Elton Soydan, MD, Ender Özal, MD, Mehmet Fethi Alişir, MD, Elif Çekirdekçi, MD, Ersin Çağrı Şimşek, MD, Gizem Ayan, MD, Murtaza Şerifi, MD, Anıl Tankı, MD, Selami Demirelli, MD, Ecenur Güder Arslan, MD, Lütfü Bekar, MD, Berna Yurttaş, MD, Naziye Ak, MD, Ahmet Çağrı Aykan, MD, Eyüp Avcı, MD, İsmail Balaban, MD, Hasan Kudat, MD, Hüsnü Değirmenci, MD, Yusuf Hoşoğlu, MD, Bedrettin Boyraz, MD, Okan Turgut, MD, Ahmet Öz, MD, Erkan Alpaslan, MD, Zeki Yüksel, MD, Çağrı Yayla, MD, Celal Kilit, MD, Ümit Yüksek, MD, San Çetin Şanlıalp, MD, Hazar Harbaloğlu, MD, Mustafa Yurttaş, MD, Mustafa Köklü, MD, Özcan Vuran, MD, Aykut Yılmaz, MD, Hasan Güngör, MD, Mehmet Ali Kaygın, MD, Onur Taşar, MD, Suat Demirkıran, MD, Gökhan Avcı, MD, Uğur Kocabaş, MD, Sara Çetin Şanlıalp, MD, İdil Gökçen Koçağra Yağız, MD, Hayri Alıcı, MD, Nazmi Gültekin, MD, Kader Eliz Uzel, MD, Mustafa Kurşun, MD, İsmail Bolat Canbolat, MD, Onur Baydar, MD, Tolga Sinan Güvenç, MD, Mehmet Çelik, MD, Ali Doğan, MD, Mehmet Erdem Toker, MD, Nurcan Arat, MD, Abdurrahman Akyüz, MD, Özgen Şafak, MD, Kaan Okyay, MD, Raşit Onuk, MD, İnanç Artaç, MD, Bilal Çuğlan, MD, Aykan Çelik, MD, Ali Gökhan Özyıldız, MD, Nurullah Çetin, MD, Özge Çetinarslan, MD, Arif Süner, MD, Cevdet Dönmez, MD, Hakan Gökaltı, MD, Uzun, MD, Sedat Köroğlu, MD, Yılmaz Ömür Otlı, MD, Vahit Demir, MD, M. Emre Durakoğlu, MD, Bülent Özlek, MD, Özgül Yıldız, MD, Sinan Çerşit, MD, Mustafa Beğenç Taşcanov, MD, Burcu Yağmur, MD, Asım Oktay Ergene, MD, Peyman Levent Türkoğlu, MD, Hasan Ali Gümrükçüoğlu, MD, Müslüm Fırat İkikardeş, MD, İnan Mutlu, MD, Çağlar Alp, MD, Uğur Canpolat, MD, Murat Samsa, MD, Fulya Avcı Demir, MD, Hüseyin Bozdemir, MD, Cenk Eray Yıldız, MD, Murat Akçay, MD, Selcen Yakar Tülüce, MD, Kamil Tülüce, MD, Murat Esin, MD, Serdar Akyel, MD, Abdullah İçli, MD, Hasan Tahsin Keçelgil, MD, Umut Kocabaş, MD, Veysel Özgür Barış, MD, Hatice Kemal, MD, Cenk Ekmekçi, MD, Mehmet Ali Kobat, MD, Mustafa Yenerçay, MD, Aytekin Aksakal, MD, Ebru Serin, MD, Fikret Keleş, MD, Çayan Çakır, MD, Yeşim Hoşcan, MD, Ahmet Haki Türkdemir, MD, Uğur Önsel Türk, MD, Özcan Başaran, MD, Şenol Tayyar, MD, İbrahim Ersoy, MD, Serhat Sığircı, MD, Kamuran Kalkan, MD, Zafer Yalın, MD, Elif İlkay Yüce, MD, Begüm Yetiş Sayın, MD, Nermin Bayar, MD, Sefa Ünal, MD, Devrim Kurt, MD, Mehmet Kış, MD, Yavuzer Koza, MD, Meltem Özyayın, MD, Adnan Doğan, MD, Hayati Eren, MD, Lale Dinç Asarcıklı, MD, Adem İlkay Diken, MD, Lütfü Bekar, MD, Sadık Volkan Emren, MD, Hazar Harbaloğlu, MD, Oğuzhan Çelik, MD, Yusuf Çekici, MD, Tolga Aksu, MD, Fatih Aytemiz, MD, Barış Buğın, MD.

Peer review under responsibility of The Society of Cardiovascular Academy.

<http://dx.doi.org/10.1016/j.ijcac.2017.06.001>

2405-8181/© 2017 The Society of Cardiovascular Academy. Production and hosting by This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Heart failure (HF) is one of the most important causes of morbidity and mortality in the world.¹ It is a big burden to healthcare economy. The prevalence is 0.4 to 2% in general European population² and 5 million Americans with chronic HF are mostly attributable to inpatient hospitalization.³ Currently approximately 26 million adults live with HF in the world and this number is substantially increasing with aging population. The prevalence is not clearly known in Turkey, but in the HAPPY study it was estimated as 2.9% in adults.⁴

Heart failure is a progressive and irreversible disorder. Therefore, prevention of HF is of great importance. At first, it is required to control risk factors of HF and leading underlying causes and then if the disease has occurred, the guidelines recommended therapy should be implemented. Survey and questionnaires are helpful to verify that real-life daily practice is keeping with what is recommended in the guidelines. Health professionals are encouraged to take the guidelines fully into account when exercising their clinical judgement, as well as in the determination and implementation of preventive, diagnostic or therapeutic medical strategies.

In this questionnaire we aimed to evaluate awareness of physicians who are interested in HF and arrhythmias about current diagnostic and therapeutic strategies of HF.

Methods

A questionnaire which consisted of 32 questions about current diagnostic and therapeutic strategies of HF and arrhythmia was used to evaluate awareness of physicians who are interested in HF and arrhythmia. The questionnaire has been sent to physicians by e-mail and they answered the questions online. At the end of 3 months the questionnaire was finalized and answers were collected. The Statistical Package for the Social Sciences software (IBM SPSS, version 21.0, SPSS Inc., Chicago, IL, USA) was used for all statistical calculations.

Results

The study groups consisted of 177 physicians (163 cardiologists, 7 cardiovascular surgeons, 6 internal medicine physicians and 1 primary care physician). Most of them have worked as physicians for 5–10 years (N: 103, 58.2%). There were 55 professors and associated professors (38%) and 122 assistant doctors and specialists (62%). Fifty-two point five percent of physicians have been worked in state hospital and 33.9% in university hospital. Less than half of the physicians (N: 71, 40.1%) have used natriuretic peptides in the diagnosis of HF and 76.3% of physicians were aware of HF with mid-range EF (HFmrEF)—patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49%. Only 5.6% of physicians were able to achieve the guidelines recommended target dose of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in more than 70% of patients with HF and reduced LVEF (HFrEF). Most of the physicians (69%) were only able to reach the treatment goals in the 41–50% of HFrEF patients. The guideline recommended treatment goals of beta blockers (BB) were achieved in >70% patients by 5.1% of physicians. More than half of the physicians (55.9%) achieved the treatment goals in <30% of patients. Despite optimal medical therapy with diuretic, ACEIs, ARBs, BB and mineralocorticoid receptor antagonists (MRAs), the ratio of physicians who have >50% symptomatic patient population were 6.8%. Twenty-seven point one of the physicians (27.1%) had symptomatic patients <25%. In a symptomatic patient despite optimal medical therapy with diuretics, ACEIs/ARBs, BB, MRAs and with sinus rhythm, QRS duration less than 120ms on surface electrocardiogram (ECG), the 83.6% of physicians selected ivabradin therapy, 11.9% digoxin therapy and 4.5% left ventricular assist device (LVAD) or heart transplantation. In this patient, angiotensin receptor neprilysin inhibitor (ARNI) was the treatment choice among 62.7% of physicians.

Interestingly, 10.2% of physicians have never heard before ARNI. Digoxin therapy was used <20% of patients with sinus rhythm on ECG among 76% of physicians. At patients with spontaneous echo contrast on echocardiography, 49.7% of physicians have selected antiplatelet therapy, 17.5% warfarin plus antiplatelet therapy and 31.6% no therapy. Among patients with stable angina pectoris, sinus rhythm, under maximum tolerated BB therapy, treatment choice was revascularization among 37.3% of physicians, trimetazidine among 8.5%, ivabradin among 16.9%, ranolazine among 12.4% and long acting nitrates among 24.9%. Most of the physicians (90.4%) have suggested searching for viability before revascularization. Carvedilol was the most chosen BB in HF patients by physicians (59.9%). Respectively, metoprolol succinate (32.8%), nebivolol and bisoprolol (3.4%) and propranolol (0.6%) were the preferred BB. Eighty-three percent (83%) of participant center had the possibility of continuous positive airway pressure for non-invasive ventilation. Only 11.3% of diabetic patients were followed by cardiologists, the rest of diabetic patients (88.7%) were referred to endocrinologist. Fifty-one (28.8%) patients suggested their patients ICD therapy independently of heart failure etiology, if LVEF is ≤40%. Forty-five patients (25.4%) considered ICD therapy for their patients, if the heart failure is ischemic origin. Only small amount of patients (11.3%) considered the hypervolemia responsible for hyponatremia >30% of patients. Left ventricular assist device (LVAD) and intra-aortic balloon pump (IABP) were achievable in 117 participant center (66.1%). When the patients were discharged from hospital, symptomatic improvement in 96% of patients, decrease of natriuretic peptides (BNP and NT pro-BNP) in 18.6% of patients, euvolemic status in 73.4% of patients as a treatment success (or surrogate). Diuretic infusion was the treatment choice in the 67.2% of patients and iv. bolus diuretic was chosen in 32.8% of patients. Seventy-four percent (74%) of physicians used low dose dopamine with iv. diuretic to increase urine output in their patients. Only 9.6% of patients used the levosimendan as an inotropic support therapy in >10% their heart failure patients. Eighty-one percent of physicians (81.4%) said that they would have chosen cardiac resynchronization therapy (CRT) if a pacemaker was necessary in a heart failure patient. We asked the physicians if they had a patient with HFrEF, NYHA II and systolic blood pressure lower than 90 mm Hg, which therapy would they have consider? The answer was low dose ACEIs and BB simultaneously in 45.8%, only BB in 26.6%, only ACEIs in 20.3%, no therapy in 6.8% and no idea in 0.5%. Sixty-one (61%) physician agreed to implant CRT-D when CRT is indicated. In a patient with acute decompensated heart failure (ADHF), pulmonary congestion and 120 mm Hg SBP, iv. diuretic and vasodilator therapy was the most preferred choice (58.8%). Most of the physicians (70.1%) did not prefer to give n-3 PUFA to their HF patients and. In a patient NYHA IV and QRS duration 118 ms, most of physicians (53.1%) did not consider ICD if the patient is not a candidate for LVAD or heart transplantation. While only 13.6% physicians had >30% patients with HFpEF, most of the physicians (30.5%) had between 21% and 30% patients with HFpEF. In a patient on BB and ivabradin therapy if the heart rate is decreased under 55 bpm, 55.9% of physician answer was to stop ivabradin therapy, 25.4% was cessation of ivabradin therapy, 4.5% was cessation of BB therapy, 10.7% was decreasing BB dosage. Only one quarter of participant center (27.7%) had heart failure polyclinic.

Discussion

Heart failure (HF) is one of the most important causes of morbidity and mortality in the world.¹ It is a big burden to healthcare economy. Currently approximately 26 million adults live with HF in the world and this number is substantially increasing with aging population. The prevalence is not clearly known in Turkey, but in the HAPPY study it was estimated as 2.9% in adults.⁴

In this questionnaire we aimed to evaluate awareness of physicians who are interested in HF and arrhythmias about current diagnostic and therapeutic strategies of HF. Most of the physicians (92.1%) was




Fig. 1. The rate of BNP use in the diagnosis of HF.

working in an university hospital (3th grade health care center in Turkey) and there were much more academican (cardiologist, associated professor and professor). Natriuretic peptides (BNP and NT-proBNP) were more pronounced in the diagnosis of HF in recent European Society of Cardiology (ESC) HF guidelines (especially in the diagnosis of HFmrEF and HFpEF).¹ Less than half of the physicians (40.1%) stated to use natriuretic peptides in the diagnosis of HF (Fig. 1). 76.3% of physicians were aware of HF with mid-range EF (HFmrEF)—patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49% and agreed that it was necessary to classify HF patients as HFrEF, HFmrEF and HFpEF according to LVEF. Unfortunately only 5.6% of physicians were able to achieve the guidelines recommended target dose of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in more than 70% of patients with HF and reduced LVEF (HFrEF). Most of the physicians (69%) were only able to reach the treatment goals in the 41–50% of HFrEF patients. Same as ACEIs, the success rate of achievement guideline recommended BB therapy was disappointing. Only 5.1% of patients were able to achieve the treatment target >70% of HF patients. Despite optimal medical therapy




Fig. 3. The rate of ARNI preference in symptomatic patients despite guideline recommended optimum medical therapy with RAAS blockers and beta blockers.

with diuretic, ACEIs, ARBs, BB and mineralocorticoid receptor antagonists (MRAs), the ratio of physicians who have more than symptomatic patient population were 6.8% (Fig. 2). In a symptomatic patient despite optimal medical therapy with RAAS blocker and BB, most of the patients have chosen ivabradin (83.6%) or ARNI (62.7%). It shows physicians who is interested in heart failure, follows the suggestion of recent HF guidelines in daily practice. Interestingly, 10.2% of physicians have never heard before ARNI (Fig. 3, group 2). In a stable angina patient, revascularization was the most preferred treatment if the angina still continues despite optimal medical therapy. Carvedilol was the most preferred BB in HF patients same as daily practice. In an asymptomatic HF patient with LVEF 40%, most of the patients did not consider ICD




Fig. 2. The symptomatic patient rate despite guideline recommended optimum medical therapy with RAAS blockers and beta blockers.

therapy. LVAD and IABP were achievable in the most center. Most of the patients considered symptomatic improvement and euvoolemia as a treatment target. Natriuretic peptides were the treatment target by only small amount of physicians (18.6%). Diuretic infusion was more preferred than iv. diuretic bolus in HF patients. This might be associated with the nature and stage of HF. If CRT is indicated most of the patients considered to implant CRT-D. Current ESC guideline on the management of HF recommends ACEIs or ARBs with BB at the same time for initiation therapy and to increase evidence-based maximum tolerated dose. The participant physicians have internalized this treatment strategy. N-3 PUFA treatment was not a highly preferred HF treatment. Current ESC guideline does not recommend ICD therapy to NYHA IV patients if they are not candidate for LVAD or heart transplantation. Most of the participants paid attention this recommendation. When we asked the proportion of HFpEF in their daily practice, 30.5% of participants emphasized that only small amount of heart failure patients in daily practice were HFpEF patients (13.6%). Only one quarter of participant center (27.7%) had heart failure polyclinic.

In this questionnaire we wanted to see a picture from daily practice of physicians who are interested in heart failure. We aimed to measure

awareness about current ESC heart failure guideline recommendations, new classification of HF according to LVEF and new diagnostic and therapeutic improvements.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

1. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *Eur Heart J* 2016;**37**:2129–2200.
2. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. *Eur Heart J* 1997;**18**:208–225.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. *Circulation* 2010;**121**:e46–e215.
4. Değertekin M, Erol C, Ergene O, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. *Turk Kardiyol Dern Ars* 2012;**40**:298–308.